ClinicalTrials.gg
RecruitingNCT07394673SPSIPUpdated Nov 3, 2026

Ultrasound-Guided Serratus Posterior Superior Intercostal Plane Block for Analgesia in Arthroscopic Shoulder Surgery

An interventional study of Group SPSIP: Serratus Posterior Superior İntercostal Plane Block (SPSIP) in Postoperative Pain, Acute, Shoulder Pain and Serratus Posterior Superior Intercostal Plane Block, sponsored by Bursa City Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Bursa City Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 3, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Pain, Postoperative by Bursa City Hospital — 13 open to participants now, 13 under way, none of them phase 3. Pain, Postoperative · Bursa City Hospital.

Planned enrollment
6th of 14
80 · median 80
Started
2026
with 13 others
No phase
14 of 17
11 open now
Primary completion
2026-09
later than 7 of 12 live
Registered
7th of 17
by date

Among the 17 studies in Pain, Postoperative by Bursa City Hospital, this one is the 6th largest by planned enrollment of the 14 interventional ones that give a count, is one of 14 that started in 2026, is one of 14 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 7th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

13 of the 17 studies in Pain, Postoperative by Bursa City Hospital are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pain, Postoperative by Bursa City Hospital, or all of them as a file.
02

Study summary

This study aimed to evaluate the effectiveness of serratus posterior superior intercostal plane (SPSIP) block in managing postoperative pain in patients undergoing arthroscopic shoulder surgery.

Read the detailed description

Most patients undergoing arthroscopic shoulder surgery report pain in the postoperative period. Pain management remains a significant concern in patient management, as it affects surgical costs, postoperative mobility, length of hospital stay, patient satisfaction, and surgical outcomes. Multimodal analgesia is recommended for the management of postoperative pain. Regional analgesia is an important component of multimodal analgesia.

The serratus posterior superior intercostal plane (SPSIP) block is a novel regional analgesia technique described in 2023. SPSIP has been reported to provide near-complete sensory blockade in the posterior neck, shoulder, and hemithorax regions.

The main objective of this study is to investigate the effectiveness of SPSIP block in patients undergoing arthroscopic shoulder surgery.

03

Conditions studied

  • Postoperative Pain, Acute
  • Shoulder Pain
  • Serratus Posterior Superior Intercostal Plane Block

Keywords

  • postoperative analgesia
  • shoulder arthroscopy
  • serratus posterior superior intercostal plane block
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Classified as (ASA) physical status I-II-III
  • Scheduled for elective shoulder arthroscopy surgery
  • Surgery performed under general anesthesia
  • Provision of written

Exclusion criteria

Exclusion Criteria:

  • Use of anticoagulant or antiplatelet medications
  • Presence of bleeding diathesis or coagulation disorders
  • Known allergy or to local anesthetics or opioid medications
  • Infection or history of previous surgery at the planned block site
  • Alcohol or drug dependence
  • Cognitive impairment preventing reliable pain assessment using the NRS
  • Pregnancy or lactation
  • Diabetes mellitus
  • Renal or hepatic impairment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Group SPSIP

    Group SPSIP Participants in this arm will receive an ultrasound-guided serratus posterior plane block .

    Procedure: Group SPSIP: Serratus Posterior Superior İntercostal Plane Block (SPSIP)

  • No intervention
    Group Control

    No block procedures will be performed on patients in this arm

Interventions

  • ProcedureGroup SPSIP: Serratus Posterior Superior İntercostal Plane Block (SPSIP)

    Serratus Posterior Superior İntercostal Plane (SPSIP) Block will be performed before the surgery in seated position, under standard sterilization conditions.A linear ultrasound probe will be placed in the sagittal plane along the medial border of the scapula, and the second and third ribs, relevant muscles, and the pleura will be identified. The needle will be advanced into the interfascial plane between the serratus posterior superior and intercostal muscles. After confirmation with salin injection , the block will be performed by injecting 30 mL of 0.25% bupivacaine, and the cranio-caudal spread will be visualized under ultrasound.

06

What researchers measure

Primary outcomes

  1. Postoperative 48-Hour PCA Opioid Consumption

    Total amount of opioid delivered by the patient-controlled analgesia (PCA) device during the first 48 hours after surgery, recorded in milligrams(mg)

    Time frame: Postoperative 0-8, 8-16, 16-24, 24-48 intervals

Secondary outcomes

  1. QoR-15 Recovery Score

    The investigators will use the Turkish version of Quality of Recovery (QoR) / QoR-15 questionairre PART A How have you been feeling in the last 24 hours? (0 to 10, where: 0 = none of the time \[poor\] and 10 = all of the time \[excellent\]) Able to breathe easily Been able to enjoy food Feeling rested Have had a good sleep Able to look after personal toilet and hygiene unaided Able to communicate with Getting support from hospital doctors and nurses Able to return to work or usual home activities Feeling comfortable and in control Having a feeling of general well-being PART B Have you had any of the following in the last 24 hours? (10 to 0, where: 10 = none of the time \[excellent\] and 0 = all of the time \[poor\]) Moderate pain Severe pain Nausea or vomiting Feeling worried or anxious Feeling sad or depressed

    Time frame: Postoperative 24th and 48th hours

  2. Dynamic and static NRS scores

    Numeric Rating Scale (NRS) (0-10 0: No pain 10: most pain felt) pain scores at rest or movement at predefined postoperative hours

    Time frame: 0, 2, 4, 8, 16, 24, and 48 hours postoperatively

  3. Total rescue analgesic dose

    Despite the use of patient-controlled analgesia (PCA), if the Numeric Rating Scale (NRS) score is ≥4 at any time point, 0.5 mg/kg intravenous meperidine will be administered as

    Time frame: Postoperative 24th and 48th hours

  4. Time of first request for rescue analgesia,

    Despite the use of patient-controlled analgesia (PCA), if the Numeric Rating Scale (NRS) score is ≥4 at any time point, 0.5 mg/kg intravenous meperidine will be administered. The time will be recorded.

    Time frame: Postoperative 48-Hours

  5. Length of Hospital Stay

    Number of days spent in hospital after surgery

    Time frame: the day of surgery, the day of discharge from the hospital

  6. Block and Opioid-Related Adverse Effects and Complications

    Block- and opioid-related adverse effects and complications, including but not limited to local anesthetic toxicity, hematoma, infection, nerve injury, nausea, vomiting, pruritus, sedation, and respiratory depression, will be recorded

    Time frame: Postoperative 48-Hours

  7. Perioperative Remifentanil infusion dose

    The amount of remifentanil administered in micrograms during general anesthesia

    Time frame: Start time: Start of anesthesia administration End time: Termination of anesthesia administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Avci O, Gundogdu O, Balci F, Tekcan MN, Ozbey M. Efficacy of serratus posterior superior intercostal plane block (SPSIPB) on post-operative pain and total analgesic consumption in patients undergoing video-assisted thoracoscopic surgery (VATS): A double-blinded randomised controlled trial. Indian J Anaesth. 2023 Dec;67(12):1116-1122. doi: 10.4103/ija.ija_589_23. Epub 2023 Dec 13. PubMed 38343684 ↗
  • Kulturoglu G, Altinsoy S, Ozguner Y, Cataroglu CK. Novel Serratus Posterior Superior Intercostal Plane Block Provided Satisfactory Analgesia after Breast Cancer Surgery: Two Case Reports. Turk J Anaesthesiol Reanim. 2024 Feb 28;52(1):33-35. doi: 10.4274/TJAR.2024.231431. PubMed 38414179 ↗
  • Tulgar S, Ciftci B, Ahiskalioglu A, Bilal B, Sakul BU, Korkmaz AO, Bozkurt NN, De Cassai A, Torres AJ, Elsharkawy H, Alici HA. Serratus Posterior Superior Intercostal Plane Block: A Technical Report on the Description of a Novel Periparavertebral Block for Thoracic Pain. Cureus. 2023 Feb 3;15(2):e34582. doi: 10.7759/cureus.34582. eCollection 2023 Feb. PubMed 36883093 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Sep 2026, 7 months.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 7 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Apr 2026 → Sep 2026 and completion Jul 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 6, 2026
StartActual
Feb 20, 2026
Primary completionActual
Sep 20, 2026was Apr 2026
CompletionEst.
Nov 20, 2026was Jul 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Bursa City Hospital · Bursa, Turkey (Türkiye)
Show 1 removed
  • Bursa City Hospital · Bursa, Turkey (Türkiye)
Nov 3, 2026
Primary completion
Apr 20, 2026→Sep 20, 2026 (actual)
Nov 3, 2026
Study completion
Jul 20, 2026→Nov 20, 2026
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    1 site added, 1 site removed
    Show site
    • Bursa City Hospital · Bursa, Turkey (Türkiye)
    Show 1 removed
    • Bursa City Hospital · Bursa, Turkey (Türkiye)
    Primary completion Apr 20, 2026→Sep 20, 2026 (now actual)
    Study completion Jul 20, 2026→Nov 20, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07394673
Lead sponsor
Bursa City Hospital
Responsible party
Merih Yıldız Eglen (Principal Investigator, MD, Bursa City Hospital) — Principal investigator
First posted
Feb 6, 2026
Start date
Feb 20, 2026
Primary completion
Sep 20, 2026
Completion
Nov 20, 2026 (estimated)
Last update
Nov 3, 2026

Study contacts

Mursel Ekinci, Assoc prof, MD
Contact
drmurselekinci@gmail.com
+905067137596
Merih Yıldız Eglen, MD
Contact
Meriheg@yahoo.com
+905059340629
Merih Yıldız Eglen, MD
principal investigator · Bursa City Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion